WHO announces the discontinuation of hydroxychloroquine treatment for new crown trials

, June 17 (Xinhua Liu Qu) The World Health Organization announced on the 17th that it will stop its "Unity Trial" project hydroxychloroquine branch trial, on the grounds that the drug has failed to reduce the death rate of new crown patients.
WHO's Department of Immunization, Vaccines and Biological Products
Restrepo said at a regular press conference the same day, based on the analysis and review of published evidence, the pilot implementation team after careful consideration decided to stop the "unity test" project hydroxychloroquine branch test.
, said internal and other external evidence from the Solidarity Trials showed that hydroxychloroquine did not reduce the patient's death rate compared to standard treatment for new crown patients.
stressed that stopping the hydroxychloroquine branch test does not constitute a WHO policy, nor is it a WHO policy recommendation. "This is what we are doing in the 'solidarity trial' for new crown patients ... WHO has different procedures for developing guidelines.
WHO said in a statement the same day, "Unity Trial" researchers will no longer randomly assign patients to the branch of hydroxychloroquine, has begun to take hydroxychloroquine but has not completed the course of treatment in the trial, can be under the guidance of a supervising physician to complete the course of treatment or stop taking.
WHO Solidarity Trials aims to compare the safety and effectiveness of several different drugs or combinations of drugs in treating neocytic pneumonia in order to find effective treatments as soon as possible.